Contact your
Local MSL
Request A Medical Science
Liaison (MSL)
Contact your
Local MSL
Request A Medical Science
Liaison (MSL)

2022 ESC/ERS Guidelines recommend risk assessments for initial diagnosis and follow-up1

Determinates of initial prognosis used in the 3-strata risk assessment

  • Signs of right HF
  • Progression of symptoms and clinical manifestations
  • Syncope
  • WHO FC
  • 6MWD*
  • CPET
  • Biomarkers: BNP or NT-proBNP
  • Echocardiography
  • cMRI
  • Hemodynamics

Depending on the severity of the clinical parameters, patients are stratified into low-, intermediate-, and high-risk groups.

The 4-strata risk assessment should be used at follow-up for prognosis

  • Patients who have been diagnosed with PAH should be assessed every 3 to 6 months

4-strata risk assessment model in PAH

Determinants of prognosis Low risk Intermediate-low risk
Points assigned 1 2
WHO FC I or II -
6MWD, m >440 320-440
BNP or NT-proBNP, ng/L <50
<300
50-199
300-649
Determinants of prognosis Intermediate-high risk High risk
Points assigned 3 4
WHO FC III IV
6MWD, m 165-319 <165
BNP or NT-proBNP, ng/L 200-800
650-1100
>800
>1100

Adapted from Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. With permission from the European Society of Cardiology and European Respiratory Society.

Learn about the proven efficacy of OPSUMIT®

See Seraphin Results

SERAPHIN PAH-related hospitalization results

View the Data

View SERAPHIN PAH-CTD subgroup data

See the Data

BACK TO TOP

*6MWD is dependent upon age, height, and burden of comorbidities.

WHO FC I and II are assigned 1 point as both are associated with good long-term survival.

6MWD=6-minute walk distance; BNP=brain natriuretic peptide; cMRI=cardiac magnetic resonance imaging; CPET=cardiopulmonary exercise testing; ERS=European Respiratory Society; ESC=European Society of Cardiology; FC=Functional Class; HF=heart failure; NT-proBNP=N-terminal pro-brain natriuretic peptide; PAH=pulmonary arterial hypertension; WHO=World Health Organization.
Reference: 1. Humbert M, Kovacs G, Hoeper MM, et al; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2022;43(38):3618-3731.

EXPAND +

+ +